FY2029 Earnings Estimate for VTYX Issued By HC Wainwright

Ventyx Biosciences, Inc. (NASDAQ:VTYX) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of Ventyx Biosciences in a research report issued on Tuesday, January 14th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($1.34) per share for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Ventyx Biosciences’ current full-year earnings is ($2.09) per share.

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Ventyx Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Ventyx Biosciences Trading Down 3.6 %

VTYX stock opened at $1.89 on Thursday. The stock has a market cap of $133.64 million, a P/E ratio of -0.80 and a beta of 0.55. Ventyx Biosciences has a twelve month low of $1.67 and a twelve month high of $11.48. The company’s 50 day moving average is $2.27 and its two-hundred day moving average is $2.28.

Insider Activity

In related news, Director Sheila Gujrathi bought 130,000 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was bought at an average cost of $2.31 per share, with a total value of $300,300.00. Following the completion of the acquisition, the director now owns 130,000 shares in the company, valued at approximately $300,300. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider John Nuss sold 21,119 shares of the firm’s stock in a transaction on Friday, December 27th. The shares were sold at an average price of $2.36, for a total value of $49,840.84. Following the completion of the transaction, the insider now owns 464,582 shares of the company’s stock, valued at approximately $1,096,413.52. This represents a 4.35 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have purchased 630,000 shares of company stock valued at $1,262,415. Company insiders own 18.18% of the company’s stock.

Institutional Trading of Ventyx Biosciences

Several institutional investors and hedge funds have recently modified their holdings of VTYX. Deerfield Management Company L.P. Series C raised its position in shares of Ventyx Biosciences by 64.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock worth $13,466,000 after purchasing an additional 2,287,570 shares during the last quarter. Sio Capital Management LLC lifted its position in shares of Ventyx Biosciences by 153.2% in the third quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock valued at $4,299,000 after acquiring an additional 1,193,024 shares in the last quarter. Vestal Point Capital LP increased its position in Ventyx Biosciences by 31.2% during the 3rd quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $3,760,000 after purchasing an additional 410,000 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Ventyx Biosciences during the 2nd quarter worth about $608,000. Finally, XTX Topco Ltd purchased a new position in Ventyx Biosciences in the 3rd quarter valued at about $246,000. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.